November 28, 2022
medcann Pharma obtaines the Good Agricultural Practices Certification (GAP) in Cannabis Production, by the Colombian Agricultural Institute – ICA, after a successful audit visit to our Production and Operations Center – in Fuentedeoro, Meta – last November 1.
This new milestone evidences, beyond compliance with the requirements established by the standard, our commitment to practices aimed at environmental, economic and social sustainability in our processes, to ensure the quality and competitiveness of our product in the local and global market.
We will continue to prioritize quality and continuous improvement to achieve, in the short term, other standards that accredit the excellence of our products and processes in the world, such as the international certification in Good Agricultural and Recollection Practices – Control Union Medical Cannabis Standard GAP (CUMCS-GAP).
November 8, 2022
Few weeks after his appointment as executive president of the Colombian Association of Cannabis Industries – Asocolcanna – Miguel Samper Strouss shares with our community an analysis of the industry within the framework of the announcements and advances in the sector in these first months of the new National Government, and the objectives he has outlined for the Association to strength it and take advantage of the opportunities opening up in this context of dynamization.
Content in Spanish
July 29, 2022
Our CEO, Carlos Adolfo Guzmán, spoke with CBD-Intel about the legalization of medical cannabis in Spain and what it means for the country, patients and the industry, along with other relevant actors from the business and political sectors. “The regulation will mainly pave the way for a more dynamic market and production of cannabis with medical purposes. This is excellent news to a firm like ours, which has always focused its efforts on producing plant genetics of quality, from licit and traceable origins, as a basic material for its farming.”
July 13, 2022
With the authorization obtained by the Spanish Agency for Medicines and Health Products (AEMPS, for its Spanish acronym Agencia Española de Medicamentos y Productos Sanitarios) medcann Europe enters the select group of 14 companies authorized for the cultivation of Cannabis plants for research purposes in Spain, which allows progress of its collaborative R&D&I project in the Basque Country with the Basque Institute for Agricultural Research and Development (NEIKER).
July 12, 2022
medcann Pharma and FASPLAN signed partnership to promote best practices in the production of elite genetics for the medical cannabis industry. The main objective of this collaboration is the union of the genetic capital of medcann Pharma and its specialization in the production of high-quality varieties, and FASPLAN knowledge and experience in the in vitro propagation of multiple plant species and the application of biotechnological techniques to advance in the production of micropropagation material of elite genetics for cannabis crops, for the local and international market.
June 17, 2022
Our genetics hit the Canadian market of medicinal cannabis, hand in hand with Klonetics Plant Science Inc.Thanks to the agreement signed between both companies, Klonetics will be able to use, develop and commercialize this genetic material in Canada, Australia, and New Zealand. “medcann is an ideal partner due to their outstanding reputation for breeding and cultivation with exceptional outdoor genetics that have been refined and tested. This is the first shipment of many to come to support outdoor and greenhouse projects with proven genetics”, said David Brough, CEO of Klonetics.
June 15, 2022
Through our subsidiary in Spain, medcann Europe, and within the collaborative R&D&I project carry out in the Basque Country with NEIKER, today we are proudly a company of the BIC Bizkaia ecosystem. The BICs are support centers for innovative entrepreneurship in the Basque Country and function as an incubator focused on sectors with high potential for generating specialized knowledge, with advanced manufacture and technology. They have a large presence of startups and consolidated companies from the biosanitary industry.
April 27, 2022
medcann Pharma strengthens its presence in Spain with the aim of becoming a leading player in the country through the supply of cannabis genetics and large-scale collaborative R&D&I projects. Learn more about our expansion and growth plans in this interview with PlantaDoce, a Spanish media specialized in the health and pharma sector.
April 7, 2022
Semana Magazine highlights the award received by medcann Pharma for contributing to the agroeconomic development of Meta. In 2016, medcann Pharma established its Production and Operations Center in the municipality of Fuentedeoro (Meta) which today is one of the company’s Research and Development hubs on cannabis genetics.
March 19, 2022
Cannabis industry opportunities in Colombia
Conversation with LatinPyme magazine about the cannabis industry in Colombia, the potential and opportunities with the new resolution 227 of 2022, and what is missing to continue consolidating the development and progress of our sector.
March 14, 2022
Our CEO´s interview with Cannabis News, about medcann’s evolution, the work currently carried out in Europe – through the group’s subsidiary in Spain – and plans for this 2022, aiming at becoming global benchmark in genetics for medical and scientific purposes.
January 29, 2022
The national medical cannabis industry continues to strengthen along with the different companies that make it up, including medcann Pharma, which has made genetics its core business. Read our CEO`s interview, Carlos Adolfo Guzmán, with the economic newspaper La República, about the company’s plans for 2022…
January 21, 2022
From Meta to the world: the company that exports cannabis genetics to Europe
Our genetics – legal and traceable to origin – are already in Europe for cannabis cultivation and extraction operations, and research projects, of two important Spanish producers of the cannabis industry for therapeutic purposes. Thanks to our clients Canamedics Labs and Cannabasa Agro&Pharma for trusting and choosing us as strategic partners.
Read news in:
January 19, 2022
FASPLAN and medcann Pharma: a new alliance to boost cannabis agricultural innovation
Our technical-scientific team works hand in hand with Fasplan, a technology-based spin-off company created in the Faculty of Pharmaceutical and Food Sciences of the University of Antioquia to carry out research, development and innovation projects in genetics improvement, and commercialization of new cannabis varieties and cultivars for medical and scientific purposes, through micropropagated plant material.
News and progress on this important alliance coming soon.
November 30, 2021
A highest level collaboration in two key front lines: Genetics Licensing and R&D
We chatted with Álvaro and Luis Comas, co-founders of Canamedics Labs, the first Catalonian company obtaining AEMPS authorization for growing cannabis with high levels of psychoactive components (THC) for research purposes. The start-up chose medcann Pharma as a strategic business partner.
“The relationship with medcann was established based in confidence, and then it was accompanied by the technical element and the quality of the genetics. Its management team in Spain, experience and portfolio of genetics – legal and traceable to origin – was fundamental at the time of choosing”.
June 30, 2021
Memberships and Associations
Since it is foundation, medcann Pharma manifests and maintains a genuine and determined interest in contributing to the development and progress of the industry, through collaborative work with key players.
• Since 2021, cannabis breeder members of CIOPORA – International Community of Breeders of Asexually Reproduced Horticultural Plant Varieties, specialized in Plant Variety Protection (PVP): patents, breeders’ rights, and registered trademarks.
• Founding members of Asocolcanna – Colombian Association of Cannabis Industries in 2017.